1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Canada Human Fibrinogen Concentrates Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Canada Human Fibrinogen Concentrates Market Revenue and Volume, by Product
8.1.1 Fibryga
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. RiaSTAP
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Volume Forecast
9.1. Canada Human Fibrinogen Concentrates Market Revenue and Volume, by Application
9.1.1. Congenital Fibrinogen Deficiency
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Acquired Fibrinogen Deficiency & Surgical Procedures
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast
10.1. Canada Human Fibrinogen Concentrates Market Revenue and Volume, by End User
10.1.1. Hospitals & ASCs
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast
11.1. Canada
11.1.1. Market Revenue and Volume Forecast, by Product
11.1.2. Market Revenue and Volume Forecast, by Application
11.1.3. Market Revenue and Volume Forecast, by End User
12.1. CSL Behring LLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Octapharma AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. LFB Group
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Grifols, S.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Baxter International Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Shanghai RAAS Blood Products Co., Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Hualan Biological Engineering Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Kedrion Biopharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Biotest AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Green Cross Corporation (GC Pharma)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
